# NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

> **NCT00206180** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 120 (—)

## Conditions studied

- Erosive Esophagitis
- Reflux Esophagitis
- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** esomeprazole magnesium (oral medication)

## Key facts

- **NCT ID:** NCT00206180
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 120 (—)
- **Last updated:** 2009-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206180, "NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00206180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*